The drug involved CTFR (Cystic fibrosis transmembrane conductance regulator), and it has also been shown that the activation of the CFTR involved in this drug inhibits the proliferation, migration and invasion of GBM cells by suppressing JAK2/STAT3 signaling (Zhong et al., 2019). The gene discussed is JAK2; the disease is glioblastoma.